Erika works with pharmaceutical and biotech clients to develop strategies for pipeline agents, evaluate commercial opportunities, and provide strategic guidance on a broad set of access-related topics. She has worked across a wide range of therapeutic areas including oncology, vaccine-preventable diseases, immunology, neurology, and rare diseases. Erika brings experience in indication prioritization assessments, clinical development strategy, strategic evidence planning, and evaluating market opportunities using qualitative and quantitative methodologies. Prior to joining Putnam in 2019, Erika earned her Ph.D. in Biological Sciences at Harvard University and Sc.M. from the Johns Hopkins Bloomberg School of Public Health.